SynBiotic 過去の業績
過去 基準チェック /06
SynBiotic's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 30.6% per year.
主要情報
-48.7%
収益成長率
-37.7%
EPS成長率
| Pharmaceuticals 業界の成長 | 7.3% |
| 収益成長率 | 30.6% |
| 株主資本利益率 | -76.6% |
| ネット・マージン | -275.3% |
| 前回の決算情報 | 31 Dec 2023 |
最近の業績更新
更新なし
Recent updates
収支内訳
SynBiotic の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -11 | 3 | 0 |
| 31 Dec 22 | 8 | -24 | 6 | 0 |
| 31 Dec 21 | 9 | -13 | 2 | 0 |
| 31 Dec 20 | 5 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
質の高い収益: SBX is currently unprofitable.
利益率の向上: SBX is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: SBX is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
成長の加速: Unable to compare SBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: SBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
株主資本利益率
高いROE: SBX has a negative Return on Equity (-76.57%), as it is currently unprofitable.